Emeritus Member | Mark Soloway, MD, FACS
Dr. Mark Soloway is Chief of Urologic Oncology at Memorial Healthcare System. He is a board-certified urologist and an internationally recognized leader in urologic oncology who has made significant contributions to the understanding and treatment of prostate, bladder and kidney cancer over a 40-year career. He earned his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio, and completed his residency in urology at University Hospitals of Cleveland. He completed his surgery branch fellowship at the National Cancer Institute of the National Institutes of Health in Bethesda, Maryland. As a clinical associate at the National Cancer Institute, NIH, where he developed an animal model for bladder cancer which is still being used to study this cancer. He was awarded the Gold Cystoscope Award by the American Urologic Association in 1984.
Dr. Soloway has contributed to the field of education with his innovative use of case-based teaching. He served as professor and chairman at the University of Miami Miller School of Medicine’s Department of Urology from 1991 until 2010.
Because of his expertise in the field of bladder cancer, he has twice been asked to chair the International Consultation on Urologic Diseases Recommendation Panel on Bladder Cancer (2004 and 2011), a committee charged with making recommendations on all aspects of bladder cancer.
Dr. Soloway has published more than 500 articles in peer-reviewed journals and has lectured extensively, both in the United States and around the world. He has popularized the case discussion format as a teaching method in an effort to assimilate scientific data into the clinic setting.Some of Dr. Soloway’s major contributions include the role of periprostatic nerve block for prostate biopsy, technical modifications in prostatectomy for prostate cancer, rationale for intravesical chemotherapy for bladder cancer and a grading scale for bone scans in prostate cancer. Dr. Soloway was one of the first to identify the efficacy of cisplatin for urothelial cancer and for the additive effect of cisplatin with radiation. Dr. Soloway chaired the International Consultation on Bladder Cancer which was sponsored by the Sociéte Internationale de Urologie (SIU). Over 100 urologists, medical oncologists, pathologists, and radiation oncologists came together to provide guidelines on bladder cancer.